Pirmenol ((±)-Pirmenol) hydrochloride is an orally active antiarrhythmic agent. Pirmenol hydrochloride inhibits I K.ACh ( IC 50 : 0.1 μM) by blocking mAchR . Pirmenol hydrochloride can be used in the research of cardiovascular disease , such as atrial fibrillation. In Vitro Pirmenol (1 μM) hydrochloride inhibits the I K.ACh induced by carbachol or intracellular loading of GTPg S in in atrial cells. Pirmenol (5 μM) hydrochloride depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes. Pirmenol (1 μM) hydrochloride prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Pirmenol (2.5 and 5 mg/kg, p.o.) hydrochloride is effective against the arrhythmias in conscious, coronary artery ligated dogs. Pirmenol (rats) hydrochloride shows LD 50 s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.). Pirmenol (mice) hydrochloride shows LD 50 s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Conscious, coronary artery ligated dogsDosage: Oral administration (p.o.) Administration: 2.5 and 5 mg/kg Result: Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin. Form:Solid IC50& Target:IC50: 0.1 μM (I K.ACh )